Management tracks: Mirati, Verastem, RedHill

Oncology company Mirati Therapeutics Inc. (NASDAQ:MRTX) named Faheem Hasnain as chairman. He succeeds Rodney Lappe, who is retiring but will remain a consulting adviser. Hasnain is executive chairman of Gossamer Bio Inc. (NASDAQ:GOSS), which raised $276 million in an upsized IPO this month (see "Gossamer Bio Prices $276M IPO").

Cancer

Read the full 495 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE